Quisinostat

DB12985InvestigationalSmall molecule

Quisinostat has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia.

Chemical structure of Quisinostat
Mechanism
Curator reviewed
Formula / weight
C21H26N6O2 · 394.479 g/mol (avg)
Code names
JNJ-26481585

Resolves to

Compound
UNII9BJ85K1J8SCAS875320-29-9ChEMBLCHEMBL2105763ChEBI94771PubChem11538455
Structure
InChIKeyPAWIYAYFNXQGAP-UHFFFAOYSA-NSMILESCN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Quisinostat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In